Literature DB >> 25335168

Common variants at 1p36 are associated with superior frontal gyrus volume.

R Hashimoto1, M Ikeda2, F Yamashita3, K Ohi4, H Yamamori5, Y Yasuda4, M Fujimoto4, M Fukunaga6, K Nemoto7, T Takahashi8, M Tochigi9, T Onitsuka10, H Yamasue9, K Matsuo11, T Iidaka12, N Iwata2, M Suzuki8, M Takeda1, K Kasai9, N Ozaki12.   

Abstract

The superior frontal gyrus (SFG), an area of the brain frequently found to have reduced gray matter in patients with schizophrenia, is involved in self-awareness and emotion, which are impaired in schizophrenia. However, no genome-wide association studies of SFG volume have investigated in patients with schizophrenia. To identify single-nucleotide polymorphisms (SNPs) associated with SFG volumes, we demonstrated a genome-wide association study (GWAS) of gray matter volumes in the right or left SFG of 158 patients with schizophrenia and 378 healthy subjects. We attempted to bioinformatically ascertain the potential effects of the top hit polymorphism on the expression levels of genes at the genome-wide region. We found associations between five variants on 1p36.12 and the right SFG volume at a widely used benchmark for genome-wide significance (P<5.0 × 10(-8)). The strongest association was observed at rs4654899, an intronic SNP in the eukaryotic translation initiation factor 4 gamma, 3 (EIF4G3) gene on 1p36.12 (P=7.5 × 10(-9)). No SNP with genome-wide significance was found in the volume of the left SFG (P>5.0 × 10(-8)); however, the rs4654899 polymorphism was identified as the locus with the second strongest association with the volume of the left SFG (P=1.5 × 10(-6)). In silico analyses revealed a proxy SNP of rs4654899 had effect on gene expression of two genes, HP1BP3 lying 3' to EIF4G3 (P=7.8 × 10(-6)) and CAPN14 at 2p (P=6.3 × 10(-6)), which are expressed in moderate-to-high levels throughout the adult human SFG. These results contribute to understand genetic architecture of a brain structure possibly linked to the pathophysiology of schizophrenia.

Entities:  

Mesh:

Year:  2014        PMID: 25335168      PMCID: PMC4350516          DOI: 10.1038/tp.2014.110

Source DB:  PubMed          Journal:  Transl Psychiatry        ISSN: 2158-3188            Impact factor:   6.222


Introduction

Schizophrenia is a common and complex psychiatric disorder with a lifetime risk of approximately 1%. This disorder has a strong genetic component; the estimated heritability is 81%.[1] Multiple genetic variants that have a small effect have been implicated in the pathogenesis of schizophrenia.[2] A genome-wide association study (GWAS) of single-nucleotide polymorphisms (SNPs) that accesses tens of thousands of DNA samples from patients and controls can be a powerful tool for identifying common risk factors for complex diseases, such as schizophrenia. GWASs on schizophrenia have identified several genome-wide significant associated variants.[3,4] Subsequently, GWASs on neurobiological quantitative traits as intermediate phenotypes that possibly reflect the underlying genetic vulnerability better than diagnostic categorization, such as schizophrenia,[5,6] have been performed to minimize the clinical and genetic heterogeneity in studies of schizophrenia.[7] The superior frontal gyrus (SFG) of the brain is frequently found to have reduced gray matter in individuals with first-episode schizophrenia and neuroleptic naive schizophrenia, as well as chronic patients with schizophrenia.[8,9] The SFG is involved in self-awareness and emotion.[10,11] Self-awareness is the cognitive ability to differentiate between self and non-self cues and is necessary to understand the behavior of other humans. Disturbance in self-awareness linked to social cognition is a core feature of schizophrenia.[12] Emotional disturbances, including meaningless laughter, are often observed in patients with schizophrenia. Meaningless laughter was also observed in unaffected siblings of schizophrenia, thus indicating its heritability.[13] In addition, laughter can be elicited by electrical stimulation of the SFG. Gray matter volumes of bilateral SFG have a strong genetic component, with an estimated heritability of 76–80%.[14] As there is considerable inter-individual variation in the degree of reduced volume of the SFG, it appears that genetic influences have a role in determining the degree of volume reduction of the SFG in schizophrenia. Although GWASs of bilateral hippocampal volume have recently been reported,[15,16] no study has investigated other brain areas in patients with schizophrenia. To identify an SNP related to SFG volumes, we conducted a GWAS of gray matter volumes in the right or left SFG of patients with schizophrenia and healthy subjects.

Materials and methods

Subjects

We selected 281 patients with schizophrenia (52.0% males, 146 males and 135 females; mean age 36.0±12.4 years) and 413 healthy controls (49.6% males, 205 males and 208 females; mean age 36.4±12.8 years) for a GWAS of schizophrenia-related phenotypes, such as structural brain morphology, neurocognitive function and neurophysiological assessments.[17, 18, 19] All of the subjects were biologically unrelated, there were no first- or second-degree relatives, and all were of Japanese descent.[20,21] The subjects were excluded if they had neurological or medical conditions that could potentially affect the central nervous system, such as atypical headaches, head trauma with loss of consciousness, chronic lung disease, kidney disease, chronic hepatic disease, thyroid disease, active cancer, cerebrovascular disease, epilepsy, seizures, substance-related disorders or mental retardation. Patients with schizophrenia were recruited from the Osaka University Hospital. Each patient had been diagnosed by at least two trained psychiatrists according to the criteria from the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) based on the Structured Clinical Interview for DSM-IV. Current symptoms of schizophrenia were evaluated using the positive and negative syndrome scale. Controls were recruited through local advertisements at Osaka University. The healthy subjects were evaluated using the non-patient version of the Structured Clinical Interview for DSM-IV to exclude individuals who had current or past contact with psychiatric services or who had received psychiatric medications. Superior frontal volumes obtained from the magnetic resonance imaging data were assessed in 158 patients with schizophrenia and 378 healthy subjects. Detailed demographic information is shown in Supplementary Table S1. Mean age and handedness did not differ significantly between the cases and controls (P>0.50); however, the gender ratio, years of education and estimated premorbid intelligence quotient differed significantly between the cases and controls (P<0.05). The ratio of male was higher in patients with schizophrenia compared with the controls. The years of education and estimated premorbid intelligence quotient were significantly lower in patients with schizophrenia compared with the controls. When the genotype groups in the top five SNPs with genome-wide significance of the right SFG volume were compared within the patient and control groups, we found no differences across the demographic variables, except for the gender ratio in the controls (rs6700718, rs1354792, rs10218584, and rs6702110; P<0.05). Written informed consent was obtained from all the subjects after the procedures had been fully explained. This study was performed in accordance with the World Medical Association's Declaration of Helsinki and was approved by the Research Ethical Committee of Osaka University.

Magnetic resonance imaging procedure and extraction of SFG volumes

All magnetic resonance imaging data were obtained using a 1.5-T GE Signa EXCITE system (Tokyo, Japan). A three-dimensional volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of 124 sagittal sections using a spoiled gradient-recalled acquisition in the steady state (SPGR) sequence (TE/TR, 4.2/12.6 ms; flip angle, 15° acquisition matrix, 256 × 256; 1NEX, FOV, 24 × 24 cm; slice thickness, 1.4 mm). We screened all scans and found no gross abnormalities, such as infarcts, hemorrhages or brain tumors, in any of the subjects. Each image was visually examined to eliminate any images with motion or metal artifacts, and the anterior commissure–posterior commissure line was adjusted.[22] MR images were processed with the VBM8 toolbox (http://dbm.neuro.uni-jena.de/vbm/download/) implemented for SPM8 (Wellcome Department of Imaging Neuroscience, University College London, UK, http://www.fil.ion.ucl.ac.uk/spm) running in MATLAB (The Mathworks, Natick, MA, USA) for tissue segmentation and anatomical normalization, as described elsewhere.[23, 24, 25] The voxel values of the normalized gray matter images were modulated according to the nonlinear component of the transformation, which resulted in approximating brain-size-adjusted gray matter volumes while preserving local volume changes.[26] Gray matter volumes of the bilateral SFG were then calculated by using the maximum probabilistic atlas using 20 hand-labeled images (Supplementary Figure S1).[27,28]

SNP selection and SNP genotyping

Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA), according to the manufacturer's protocol. The genotypes were called from the CEL files using Birdseed v2 for the 6.0 chip implemented in the Genotyping Console software (Affymetrix). We then applied the following quality control (QC) criteria to exclude samples: (i) arrays with low QC (<0.4) according to Birdseed v2 (N=0), (ii) samples for which <95% of the genotypes were called (N=0) and (iii) samples in the same family according to π̂ (>0.4, N=0). Next, we excluded SNPs that: (i) had low call rates (<0.95), (ii) were duplicated, (iii) were localized to sex chromosomes, (iv) deviated from Hardy–Weinberg equilibrium in the controls (P<0.0001) or (v) had low minor allele frequencies <0.05. After all of these exclusions, 517 946 SNPs that underwent QC remained for experimental analysis. To test for the existence of a genetic structure in the data, we performed a principal component analysis using EIGENSTRAT 3.0 software.[29] Ten eigenvectors were calculated. Genotype information from the JPT (Japanese in Tokyo, Japan), CHB (Han Chinese in Beijing, China), CEU (Utah residents with ancestors from northern and western Europe) and YRI (Yoruba in Ibadan, Nigeria) in HapMap phase III was compared with our data set to check for population stratification (Supplementary Figure S2).

Statistical analyses

Statistical analyses of the demographic variables were performed using PASW Statistics 18.0 software (SPSS Japan, Tokyo, Japan). Differences in the clinical characteristics between patients and controls were analyzed using χ tests for the categorical variables and the Mann–Whitney U-test for the continuous variables. Multiple linear regression analysis was performed to compare the gray matter volumes in the right and left SFG regions among genotypes (the number of major alleles; 0, 1 or 2) using PLINK 1.07 software. Diagnosis, age and gender were included as covariates. Quantile–Quantile is listed in Supplementary Figure S3.

Results

We observed associations between five variants (rs4654899, rs6702110, rs6700718, rs10218584 and rs1354792) on 1p36.12 and the right SFG volume at a widely used benchmark for genome-wide significance (P<5.0 × 10−8, r among SNPs >0.8; Figure 1). The strongest association was observed at rs4654899, an intronic SNP in the eukaryotic translation initiation factor 4 gamma, 3 (EIF4G3) gene on 1p36.12 (P=7.5 × 10−9; Figure 2). No SNP with genome-wide significance was found in the volume of the left SFG; however, the rs4654899 polymorphism was identified as the locus with the second strongest association with the volume of the left SFG (P=1.5 × 10−6; Figure 1). The top 10 and top 200 markers on each SFG are shown in Tables 1 and 2 and Supplementary Tables S2 and S3. Post hoc analyses separately assessed in patients and controls also revealed reduced but significant associations (Tables 1 and 2 and Supplementary Tables S2 and S3). Genotype effects of rs4654899 on gray matter volume of right superior frontal gyrus were found in patients with schizophrenia and controls (Figure 3). We attempted to bioinformatically ascertain the potential effects of the rs4654899 polymorphism on the expression levels of genes at the genome-wide region by using the mRNA by SNP Browser 1.0.1 database (http://www.sph.umich.edu/csg/liang/asthma/). Significant effects of the rs3767248 proxy SNP for rs4654899 (r=1.0) were identified in the expressions of the heterochromatin protein 1, binding protein 3 (HP1BP3) gene (P=7.8 × 10−6), which lies 3′ to EIF4G3, as a cis-acting effect (<200 kb), and the calpain 14 (CAPN14) gene (P=6.3 × 10−6), as a trans-acting effect (>200 kb; Supplementary Table S4). Both HP1BP3 and CAPN14 are expressed in moderate-to-high levels throughout the adult human SFG (Supplementary Figures S4 and Supplementary Figure S5), as visualized in the Allen Institute Human Brain Atlas Explorer 2 software (http://human.brain-map.org/static/brainexplorer).
Figure 1

Manhattan plots derived from the multiple linear regression analysis of the bilateral superior frontal volumes. The blue line indicates a P-value of 1.0E−05. The red line indicates a P-value of 5.0E−08.

Figure 2

The strongest association with the right superior frontal gyrus was found for rs4654899. P-values (−log10) are shown in regions peripheral to rs4654899 (±750 kb).

Table 1

TOP 10 SNPs for the right superior frontal gyrus

RankSNPChrBpmMMAFCombined subjects
Schizophrenia
Controls
Closest gene
       NβPNβPNβP 
1rs4654899121410231AC0.33509−969.57.52E−09153−11643.71E−04356−935.91.86E−06EIF4G3
2rs6702110121515906GA0.32526−965.31.07E−08155−12551.79E−04371−902.34.34E−06EIF4G3
3rs6700718121299363AC0.33537−895.12.89E−08159−11104.68E−04378−847.76.81E−06EIF4G3
4rs10218584121474480GC0.33537−891.83.21E−08159−11104.68E−04378−842.77.68E−06EIF4G3
5rs1354792121391875CT0.33535−892.73.46E−08157−11145.35E−04378−847.76.81E−06EIF4G3
6rs6703227121374810CT0.33537−879.35.28E−08159−10569.55E−04378−847.76.81E−06EIF4G3
7rs1609558121525228CT0.30533−899.85.36E−08158−10311.18E−03375−870.97.67E−06EIF4G3
8rs12402486121447935AG0.34527−880.95.58E−08159−11104.68E−04368−8301.20E−05EIF4G3
9rs2874367121324491AC0.33531−874.57.19E−08157−10926.24E−04374−8291.25E−05EIF4G3
10rs6945071726122423GA0.16537−10358.46E−07159−11203.25E−03378−983.21.02E−04NFE2L3

Abbreviations: Chr, chromosome; Bp, nucleotide location; m, minor allele; M, major allele; MAF, minor allele frequency; SNP, single-nucleotide polymorphism. Genome-wide significant P-values are shown as bold font and are underlined.

Table 2

TOP 10 SNPs for the left superior frontal gyrus

RankSNPChrBpmMMAFCombined subjects
Schizophrenia
Controls
Closest gene
       NβPNβPNβP 
1rs4574391427212223CT0.25533−8807.63E−07158−6934.27E−02375−9653.51E−06STIM2
2rs4654899121410231AC0.33509−7871.51E−06153−6913.81E−02356−8634.22E−06EIF4G3
3rs2046701427211040CA0.25532−8262.22E−06158−6973.87E−02374−8871.28E−05STIM2
4rs1609558121525228CT0.3533−7632.33E−06158−5241.11E−01375−8851.67E−06EIF4G3
5rs6702110121515906GA0.32526−7693.37E−06155−7143.90E−02371−8349.21E−06EIF4G3
6rs10218584121474480GC0.33537−7048.32E−06159−5668.48E−02378−7911.05E−05EIF4G3
7rs1354792121391875CT0.33535−7048.69E−06157−6255.92E−02378−7761.59E−05EIF4G3
8rs2623384399064220GA0.39525−7249.15E−06157−8946.79E−03368−6425.92E−04COL8A1
9rs22923431745455670CG0.34524−7219.74E−06155−8361.22E−02369−6663.45E−04EFCAB13
10rs38833171745484111AG0.34534−7031.03E−05158−7432.70E−02376−6751.72E−04EFCAB13

Abbreviations: Chr, chromosome; Bp, nucleotide location; m, minor allele; M, major allele; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.

Figure 3

Impact of the rs4654899 genotype of the EIF4G3 gene on the right superior frontal gyrus. Each column shows relative gray matter volumes of the right superior frontal gyrus. Error bars represent the standard error.

Discussion

To date, it remained unclear whether there were genetic variants strongly related to SFG volume in patients with schizophrenia and healthy subjects. This study is the first GWAS to identify the SNPs associated with the SFG, which have an important role in schizophrenia-related social functions and is reduced in patients with schizophrenia. We revealed that there were associations at the genome-wide significant level between SFG and genetic variants of the EIF4G3 gene on 1p36.12. Individuals with minor A-allele of the most significant variant rs4654899 had smaller right SFG volumes compared with those with major C-allele in both patients and controls. Bioinformatical data indicate that the rs3767248 proxy SNP for rs4654899 has important roles in the expression of the HP1BP3 and CAPN14 genes, which are expressed in human adult SFG. The HP1BP3 and CAPN14 gene expressions of the minor G-allele of the rs3767248 polymorphism were significantly lower than those of the major A-allele. However, whether the expression levels of these genes in the brains or serums of patients with schizophrenia are lower or higher than those in healthy subjects is unknown. Further study is needed to investigate the difference of the expressions between patients and controls. To our knowledge, no study has reported associations between these genes and schizophrenia, although the chromosomal region (1p36.12) related to the risk of schizophrenia has been reported.[30] The exact functions of these two genes are unknown; however, HP1BP3 is predicted to bind to DNA and have a role in nucleosome assembly. CAPN14, which belongs to the calpain large subunit family, is a cytosolic calcium-activated cysteine protease involved in a variety of cellular processes, including apoptosis, cell division, modulation of integrin–cytoskeletal interactions and synaptic plasticity. In this study, we examined the effects of genotypes on SFG volumes in a combined sample of patients and controls, and found similar effects of genotypes in patients and controls. Susceptibility genes for schizophrenia do not directly encode for their clinical syndrome/behaviors. The syndrome/behaviors observed in schizophrenia are produced by intermediate steps that occur between genes and syndrome/behaviors; and intermediate steps, such as changes of brain volumes, underlie the syndrome/behavior of schizophrenia. The intermediate phenotypes are located on the pathogenesis path, and are likely associated with a more basic and proximal etiological process rather than pathogenesis of disease itself.[5,6] Therefore, each genetic variant is related to controls as well as patients, and accumulations of each genetic variant could contribute to pathogenesis of schizophrenia through intermediate steps. To date, although abnormal brain lateralization in schizophrenia causing a failure of left hemisphere dominance has been reported,[31] there is no evidence of SFG lateralization in schizophrenia. In addition, there is no report for developmental/functional differences between the right and left SFG. We found genome-wide significant variants related to right SFG volumes, whereas these variants were not related to left SFG volumes at genome-wide significant level. The difference of significance between right and left SFG was due to a difference of genotype effects in patients (for example, rs4654899, right: P=3.71 × 10−4, left: P=3.81 × 10−2) but not in controls (right: P=1.86 × 10−6, left: P=4.22 × 10−6). As it has been reported that gray matter volume deficits were more extensive in individuals with first-episode schizophrenia and neuroleptic naive than that of their neuroleptic-treated counterparts in left SFG,[9] confounding factors, such as duration of antipsychotic treatment or dose of antipsychotics, might affect our results. In this study, we provide new insights into the genetic architecture of a brain structure closely linked to schizophrenia. It is still unclear whether and to what extent the effects of the genetic variant on SFG volumes observed here might be associated with an increased risk for schizophrenia. We suggest that the variant may have a role in the impairments of self-awareness and emotion noted in patients with schizophrenia through volumetric vulnerability of the SFG. There were several limitations to this study. We recruited a relatively large sample with an only Japanese ethnicity to avoid population stratification. However, the existence of a false-positive association cannot be excluded as an explanation for our results. Further investigations of other samples with much larger sample sizes and/or with different ethnicities are needed to confirm our findings. It is unclear whether our results are directly/indirectly linked to the rs4654899 SNP, to other SNPs in high linkage disequilibrium with this SNP or to interactions between this SNP and other SNPs. To determine whether rs4654899 is the most strongly associated variant for SFG volume in the chromosomal region, an extensive search such as sequencing for other functional variants at this locus could provide further information underlying the genomic mechanism for this variant. In conclusion, we found that genetic variants of the EIF4G3 gene could be associated with structural vulnerability of the SFG. Further replication studies are necessary to confirm our findings. Identification of causal variants and the functional effects of these genes may help to reveal additional genetic variables involved in the neurodevelopment and pathogenesis of schizophrenia.
  30 in total

1.  The KCNH2 gene is associated with neurocognition and the risk of schizophrenia.

Authors:  Ryota Hashimoto; Kazutaka Ohi; Yuka Yasuda; Motoyuki Fukumoto; Hidenaga Yamamori; Kouzin Kamino; Takashi Morihara; Masao Iwase; Hiroaki Kazui; Masatoshi Takeda
Journal:  World J Biol Psychiatry       Date:  2011-09-22       Impact factor: 4.132

2.  A voxel-based morphometric study of ageing in 465 normal adult human brains.

Authors:  C D Good; I S Johnsrude; J Ashburner; R N Henson; K J Friston; R S Frackowiak
Journal:  Neuroimage       Date:  2001-07       Impact factor: 6.556

3.  The AKT1 gene is associated with attention and brain morphology in schizophrenia.

Authors:  Kazutaka Ohi; Ryota Hashimoto; Yuka Yasuda; Motoyuki Fukumoto; Kiyotaka Nemoto; Takashi Ohnishi; Hidenaga Yamamori; Hidetoshi Takahashi; Naomi Iike; Kouzin Kamino; Tetsuhiko Yoshida; Michiyo Azechi; Koji Ikezawa; Hitoshi Tanimukai; Shinji Tagami; Takashi Morihara; Masayasu Okochi; Toshihisa Tanaka; Takashi Kudo; Masao Iwase; Hiroaki Kazui; Masatoshi Takeda
Journal:  World J Biol Psychiatry       Date:  2011-12-12       Impact factor: 4.132

4.  A prospective cohort study of childhood behavioral deviance and language abnormalities as predictors of adult schizophrenia.

Authors:  C E Bearden; I M Rosso; J M Hollister; L E Sanchez; T Hadley; T D Cannon
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

Review 5.  Schizophrenia, consciousness, and the self.

Authors:  Louis A Sass; Josef Parnas
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

6.  Genome-wide association study of cognitive decline in schizophrenia.

Authors:  Ryota Hashimoto; Masashi Ikeda; Kazutaka Ohi; Yuka Yasuda; Hidenaga Yamamori; Motoyuki Fukumoto; Satomi Umeda-Yano; Dwight Dickinson; Branko Aleksic; Masao Iwase; Hiroaki Kazui; Norio Ozaki; Daniel R Weinberger; Nakao Iwata; Masatoshi Takeda
Journal:  Am J Psychiatry       Date:  2013-06       Impact factor: 18.112

7.  Identification of common variants associated with human hippocampal and intracranial volumes.

Authors:  Jason L Stein; Sarah E Medland; Alejandro Arias Vasquez; Derrek P Hibar; Rudy E Senstad; Anderson M Winkler; Roberto Toro; Katja Appel; Richard Bartecek; Ørjan Bergmann; Manon Bernard; Andrew A Brown; Dara M Cannon; M Mallar Chakravarty; Andrea Christoforou; Martin Domin; Oliver Grimm; Marisa Hollinshead; Avram J Holmes; Georg Homuth; Jouke-Jan Hottenga; Camilla Langan; Lorna M Lopez; Narelle K Hansell; Kristy S Hwang; Sungeun Kim; Gonzalo Laje; Phil H Lee; Xinmin Liu; Eva Loth; Anbarasu Lourdusamy; Morten Mattingsdal; Sebastian Mohnke; Susana Muñoz Maniega; Kwangsik Nho; Allison C Nugent; Carol O'Brien; Martina Papmeyer; Benno Pütz; Adaikalavan Ramasamy; Jerod Rasmussen; Mark Rijpkema; Shannon L Risacher; J Cooper Roddey; Emma J Rose; Mina Ryten; Li Shen; Emma Sprooten; Eric Strengman; Alexander Teumer; Daniah Trabzuni; Jessica Turner; Kristel van Eijk; Theo G M van Erp; Marie-Jose van Tol; Katharina Wittfeld; Christiane Wolf; Saskia Woudstra; Andre Aleman; Saud Alhusaini; Laura Almasy; Elisabeth B Binder; David G Brohawn; Rita M Cantor; Melanie A Carless; Aiden Corvin; Michael Czisch; Joanne E Curran; Gail Davies; Marcio A A de Almeida; Norman Delanty; Chantal Depondt; Ravi Duggirala; Thomas D Dyer; Susanne Erk; Jesen Fagerness; Peter T Fox; Nelson B Freimer; Michael Gill; Harald H H Göring; Donald J Hagler; David Hoehn; Florian Holsboer; Martine Hoogman; Norbert Hosten; Neda Jahanshad; Matthew P Johnson; Dalia Kasperaviciute; Jack W Kent; Peter Kochunov; Jack L Lancaster; Stephen M Lawrie; David C Liewald; René Mandl; Mar Matarin; Manuel Mattheisen; Eva Meisenzahl; Ingrid Melle; Eric K Moses; Thomas W Mühleisen; Matthias Nauck; Markus M Nöthen; Rene L Olvera; Massimo Pandolfo; G Bruce Pike; Ralf Puls; Ivar Reinvang; Miguel E Rentería; Marcella Rietschel; Joshua L Roffman; Natalie A Royle; Dan Rujescu; Jonathan Savitz; Hugo G Schnack; Knut Schnell; Nina Seiferth; Colin Smith; Vidar M Steen; Maria C Valdés Hernández; Martijn Van den Heuvel; Nic J van der Wee; Neeltje E M Van Haren; Joris A Veltman; Henry Völzke; Robert Walker; Lars T Westlye; Christopher D Whelan; Ingrid Agartz; Dorret I Boomsma; Gianpiero L Cavalleri; Anders M Dale; Srdjan Djurovic; Wayne C Drevets; Peter Hagoort; Jeremy Hall; Andreas Heinz; Clifford R Jack; Tatiana M Foroud; Stephanie Le Hellard; Fabio Macciardi; Grant W Montgomery; Jean Baptiste Poline; David J Porteous; Sanjay M Sisodiya; John M Starr; Jessika Sussmann; Arthur W Toga; Dick J Veltman; Henrik Walter; Michael W Weiner; Joshua C Bis; M Arfan Ikram; Albert V Smith; Vilmundur Gudnason; Christophe Tzourio; Meike W Vernooij; Lenore J Launer; Charles DeCarli; Sudha Seshadri; Ole A Andreassen; Liana G Apostolova; Mark E Bastin; John Blangero; Han G Brunner; Randy L Buckner; Sven Cichon; Giovanni Coppola; Greig I de Zubicaray; Ian J Deary; Gary Donohoe; Eco J C de Geus; Thomas Espeseth; Guillén Fernández; David C Glahn; Hans J Grabe; John Hardy; Hilleke E Hulshoff Pol; Mark Jenkinson; René S Kahn; Colm McDonald; Andrew M McIntosh; Francis J McMahon; Katie L McMahon; Andreas Meyer-Lindenberg; Derek W Morris; Bertram Müller-Myhsok; Thomas E Nichols; Roel A Ophoff; Tomas Paus; Zdenka Pausova; Brenda W Penninx; Steven G Potkin; Philipp G Sämann; Andrew J Saykin; Gunter Schumann; Jordan W Smoller; Joanna M Wardlaw; Michael E Weale; Nicholas G Martin; Barbara Franke; Margaret J Wright; Paul M Thompson
Journal:  Nat Genet       Date:  2012-04-15       Impact factor: 38.330

8.  Impact of the genome wide supported NRGN gene on anterior cingulate morphology in schizophrenia.

Authors:  Kazutaka Ohi; Ryota Hashimoto; Yuka Yasuda; Kiyotaka Nemoto; Takashi Ohnishi; Motoyuki Fukumoto; Hidenaga Yamamori; Satomi Umeda-Yano; Takeya Okada; Masao Iwase; Hiroaki Kazui; Masatoshi Takeda
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

9.  Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe.

Authors:  Alexander Hammers; Richard Allom; Matthias J Koepp; Samantha L Free; Ralph Myers; Louis Lemieux; Tejal N Mitchell; David J Brooks; John S Duncan
Journal:  Hum Brain Mapp       Date:  2003-08       Impact factor: 5.038

10.  The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia.

Authors:  Kazutaka Ohi; Ryota Hashimoto; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Satomi Umeda-Yano; Masaki Fukunaga; Yoshiyuki Watanabe; Masao Iwase; Hiroaki Kazui; Masatoshi Takeda
Journal:  Behav Brain Funct       Date:  2013-10-25       Impact factor: 3.759

View more
  10 in total

Review 1.  Calpain-14 and its association with eosinophilic esophagitis.

Authors:  Vladislav A Litosh; Mark Rochman; Jeffrey K Rymer; Aleksey Porollo; Leah C Kottyan; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2017-01-25       Impact factor: 10.793

Review 2.  Opportunities for an enhanced integration of neuroscience and genomics.

Authors:  Ashlee A Moore; Chelsea Sawyers; Daniel E Adkins; Anna R Docherty
Journal:  Brain Imaging Behav       Date:  2018-08       Impact factor: 3.978

3.  Genetic Variants Associated with Neuropeptide Y Autoantibody Levels in Newly Diagnosed Individuals with Type 1 Diabetes.

Authors:  Sara Juul Mansachs; Sofie Olund Villumsen; Jesper Johannesen; Alexander Lind; Simranjeet Kaur; Flemming Pociot
Journal:  Genes (Basel)       Date:  2022-05-12       Impact factor: 4.141

4.  Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression.

Authors:  Andy R Eugene; Jolanta Masiak
Journal:  Brain (Bacau)       Date:  2014-12

Review 5.  Imaging genetics and psychiatric disorders.

Authors:  R Hashimoto; K Ohi; H Yamamori; Y Yasuda; M Fujimoto; S Umeda-Yano; Y Watanabe; M Fukunaga; M Takeda
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

6.  Genome-wide Association Analysis of Eye Movement Dysfunction in Schizophrenia.

Authors:  Masataka Kikuchi; Kenichiro Miura; Kentaro Morita; Hidenaga Yamamori; Michiko Fujimoto; Masashi Ikeda; Yuka Yasuda; Akihiro Nakaya; Ryota Hashimoto
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

7.  A 1.5-Year Longitudinal Study of Social Activity in Patients With Schizophrenia.

Authors:  Kazutaka Ohi; Chika Sumiyoshi; Haruo Fujino; Yuka Yasuda; Hidenaga Yamamori; Michiko Fujimoto; Tomiki Sumiyoshi; Ryota Hashimoto
Journal:  Front Psychiatry       Date:  2019-08-09       Impact factor: 4.157

Review 8.  Trends in big data analyses by multicenter collaborative translational research in psychiatry.

Authors:  Toshiaki Onitsuka; Yoji Hirano; Kiyotaka Nemoto; Naoki Hashimoto; Itaru Kushima; Daisuke Koshiyama; Michihiko Koeda; Tsutomu Takahashi; Yoshihiro Noda; Junya Matsumoto; Kenichiro Miura; Takanobu Nakazawa; Takatoshi Hikida; Kiyoto Kasai; Norio Ozaki; Ryota Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2022-01       Impact factor: 12.145

9.  Altered sulcogyral patterns of orbitofrontal cortex in a large cohort of patients with schizophrenia.

Authors:  Shuichi Isomura; Ryota Hashimoto; Motoaki Nakamura; Yoji Hirano; Fumio Yamashita; Shin Jimbo; Hidenaga Yamamori; Michiko Fujimoto; Yuka Yasuda; Ryan P Mears; Toshiaki Onitsuka
Journal:  NPJ Schizophr       Date:  2017-01-12

Review 10.  Neuroimaging studies within Cognitive Genetics Collaborative Research Organization aiming to replicate and extend works of ENIGMA.

Authors:  Daisuke Koshiyama; Kenichiro Miura; Kiyotaka Nemoto; Naohiro Okada; Junya Matsumoto; Masaki Fukunaga; Ryota Hashimoto
Journal:  Hum Brain Mapp       Date:  2020-06-05       Impact factor: 5.038

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.